Top Markets
#1 MowCat MowCat +48.94%
#2 Velvet Velvet +24.42%
#3 Bermuda Shorts Bermuda Shorts +24.20%
#4 Quack AI Quack AI +22.94%
#5 Derive Derive +20.22%
#6 Audiera Audiera +19.04%
#7 Biconomy Biconomy +18.54%
#8 Geodnet Geodnet +14.53%
#9 aPriori aPriori +14.25%
#10 SkyAI SkyAI +13.63%
Coin of the day
MowCat MowCat
設定
言語
日本
通貨
USD
テーマ
IMV Inc. IMV Inc.

IMV Inc.

IMV
株式のランク #35289
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
株価
$0.82959892
最終同期: 2023-05-23
時価総額
$4.16M
変化（1日）
-0.04%
変化（1年）
0.00%
国
CA
取引 IMV Inc. (IMV)

カテゴリー

Healthcare
IMV Inc.（IMV）のP/B比率
2026 時点のP/B比率 TTM: 0
IMV Inc. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 0 です。2026 年末時点でのP/B比率は 0 でした。
IMV Inc. の P/B 比率の履歴（2026 ～ 2026）
各年末時点のP/B比率
年 P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE